Selling Stockholders

# of Shares Beneficially Owned Prior to the
Offering

% of Issued and Outstanding Shares Owned Prior to the
Offering ⁽¹⁾

# of Shares Registered and to be Sold in this
Offering ⁽²⁾

# of Shares Beneficially Owned After this
Offering ⁽²⁾

% of Issued and Outstanding Shares Owned After this
Offering ⁽²⁾

Jörg Gerlach, MD PhD ⁽³⁾

*

Kalen Capital Holdings LLC ⁽⁴⁾

Total

*

Less than 1%

⁽¹⁾

Calculated pursuant to Rule 13d-3(d) of the Exchange Act. Beneficial ownership is calculated based on 69,955,847 shares of common stock issued and outstanding as of the date of this prospectus supplement. Under Rule 13d-3(d) of the Exchange Act, shares not outstanding which are subject to options, warrants, rights or conversion privileges exercisable within 60 days are deemed outstanding for the purpose of calculating the number and percentage owned by such person, but are not deemed outstanding for the purpose of calculating the percentage owned by each other person listed.

Under Rule 13d-3, a beneficial owner of a security includes any person who, directly or indirectly, through any contract, arrangement, understanding, relationship, or otherwise has or shares: (i) voting power, which includes the power to vote, or to direct the voting of shares; and (ii) investment power, which includes the power to dispose or direct the disposition of shares. Certain shares may be deemed to be beneficially owned by more than one person (if, for example, persons share the power to vote or the power to dispose of the shares). In addition, shares are deemed to be beneficially owned by a person if the person has the right to acquire the shares (for example, upon exercise of an option) within 60 days of the date as of which the information is provided. In computing the percentage ownership of any person, the amount of shares outstanding is deemed to include the amount of shares beneficially owned by such person (and only such person) by reason of these acquisition rights. As a result, the percentage of outstanding shares of any person as shown in this table does not necessarily reflect the person's actual ownership or voting power with respect to the number of shares of common stock actually outstanding as of the date of this prospectus supplement.

⁽²⁾

The Selling Stockholders may offer and sell, from time to time, any or all of our common stock issued to them and registered for resale. Because the Selling Stockholders may offer all or only some portion of the 10,740,000 shares of common stock registered, no exact number can be given as to the amount or percentage of these shares of common stock that will be held by the Selling Stockholders upon termination of the offering. We can only make estimates and assumptions. The number of shares listed in the category titled "% of Issued and Outstanding Shares Owned After This Offering," in the table above, represent an estimate of the number of shares of common stock that will be held by the Selling Stockholders after the offering. To arrive at this estimate, we have assumed that the Selling Stockholders will sell all of the shares to be registered pursuant to this offering and will not be acquiring any additional shares. Please refer to "Plan of Distribution."

⁽³⁾

As part of our acquisition of the CellMist^TM System from Dr. Gerlach we issued him a Series A Warrant to purchase up to 1,200,000 shares of our common stock at an exercise price of $0.35 per share. The Series A Warrant vests in five equal installments of 240,000 on July 12, 2014-2018 and expires on July 12, 2019. During 2015, Dr. Gerlach exercised on a cashless basis 240,000 vested Series A Warrants resulting in the issuance 196,812 shares of common stock.

⁽⁴⁾

Kalen Capital Holdings LLC (“KCH”) is a wholly owned subsidiary of Kalen Capital Corporation (“KCC”), a private Alberta corporation wholly owned by Mr. Harmel Rayat. In such capacity, Mr. Rayat may be deemed to have beneficial ownership of these shares. The number of shares reflected above is as of November 9, 2016, based upon the review of our transfer records as of said date and information provided to us by KCC and includes: (a) 44,550,713 shares of our common stock owned by KCC and its wholly owned subsidiary; (b) a Series B Warrant to purchase up to 1,326,087 shares of our common stock at an exercise price of $0.46 per share through November 29, 2018; (c) a Series C Warrant to purchase up to 3,500,000 shares of our common stock at an exercise price of $0.49 per share through November 29, 2018; (d) a Series D Warrant to purchase up to 800,000 shares of our common stock at an exercise price of $1.10 per share through June 5, 2020; (e) a Series E Warrant to purchase up to 584,416 shares of our common stock at an exercise price of the lesser of (i) $1.54 or (ii) a 20% discount to the average closing price of our common stock as quoted on the OTCQB for the 5 days prior to the date on which KCC elects to exercise the warrant through September 9, 2021; and (f) 910,591 shares issuable upon exercise of a convertible note in the principal amount of $700,000 and accrued interest, based upon a conversion price of $0.7776, representing a 20% discount to our closing price for the 5 days prior to November 9, 2016 (as of the date of this prospectus supplement, we have not received a notice of conversion from KCC). Each of the foregoing warrants may be exercised on a cashless basis using the formula contained therein. For tax purposes, all of the debt and equity securities of the Company owned by KCC have been assigned to KCH.

⁽⁵⁾

KCH's beneficial ownership and ownership percentage have been calculated in accordance with Rule 13d-3(c) of the Exchange Act, which provides that all securities of the same class beneficially owned by a person, regardless of the form which such beneficial ownership takes, shall be aggregated in calculating the number of shares beneficially owned by such person and in accordance with Rule 13d-3(d) of the Exchange Act.

3